Congratulations on the successful publication of this special review series on nonalcoholic fatty liver disease (NAFLD). I would like to express my sincere gratitude to the renowned hepatologists who willingly agreed to participate as authors, and to the Editor-in-Chief, Professor Seung Up Kim, and the members of the editorial board for their dedication and hard work.
Clinical and Molecular Hepatology (CMH) is the official journal of the Korean Association for the Study of the Liver (KASL), and it aims to share the latest knowledge through the publication of distinguished research in the field of hepatology. CMH started as ‘The Korean Journal of Hepatology’ in 1995, and changed its name to CMH from 2012. CMH has continuously developed through the submission of outstanding papers by numerous domestic and foreign researchers, and has been listed in the Science Citation Index Expanded since November 2019. Today, CMH continues to develop rapidly as one of Asia’s leading hepatology journals.
I believe the commendable attempt to publish this special review series on NAFLD reflects the constant effort made by the editorial board members, which has led to such developments of CMH . In the future, I look forward to publishing various special review series on diverse liver diseases, which will cover the most up-to-date as well as controversial topics. CMH and the KASL will continuously pursue novel changes and strive for further development in research. I hope that the publication of this special review series on NAFLD will serve as an opportunity for CMH to advance one more step. Furthermore, I hope this review will also provide a forum for researchers to share their achievements and innovative ideas through active intellectual collaboration, and ultimately contribute to improving patient care and research in the field of hepatology.
Citations
Citations to this article as recorded by
